175 related articles for article (PubMed ID: 1353743)
1. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.
Rachmilewitz D; Karmeli F; Schwartz LW; Simon PL
Gut; 1992 Jul; 33(7):929-32. PubMed ID: 1353743
[TBL] [Abstract][Full Text] [Related]
2. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
Roediger W; Schapel G; Lawson M; Radcliffe B; Nance S
Biochem Pharmacol; 1986 Jan; 35(2):221-5. PubMed ID: 2867767
[TBL] [Abstract][Full Text] [Related]
3. Cytokines and platelet-activating factor in human inflamed colonic mucosa.
Rachmilewitz D; Eliakim R; Simon P; Ligumsky M; Karmeli F
Agents Actions; 1992; Spec No():C32-6. PubMed ID: 1359744
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.
Mahida YR; Lamming CE; Gallagher A; Hawthorne AB; Hawkey CJ
Gut; 1991 Jan; 32(1):50-4. PubMed ID: 1846838
[TBL] [Abstract][Full Text] [Related]
6. Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa.
Kolassa N; Becker R; Wiener H
Prostaglandins; 1985 Jan; 29(1):133-42. PubMed ID: 2858116
[TBL] [Abstract][Full Text] [Related]
7. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
Bird HA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
[TBL] [Abstract][Full Text] [Related]
8. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.
Craven PA; Pfanstiel J; Saito R; DeRubertis FR
Gastroenterology; 1987 Jun; 92(6):1998-2008. PubMed ID: 2883067
[TBL] [Abstract][Full Text] [Related]
9. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat.
Gálvez J; Garrido M; Merlos M; Torres MI; Zarzuelo A
Br J Pharmacol; 2000 Aug; 130(8):1949-59. PubMed ID: 10952687
[TBL] [Abstract][Full Text] [Related]
10. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucyl-phenylalanine-induced mucosal injury in rat ileum.
von Ritter C; Grisham MB; Granger DN
Gastroenterology; 1989 Mar; 96(3):811-6. PubMed ID: 2563347
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
13. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.
Eliakim R; Karmeli F; Chorev M; Okon E; Rachmilewitz D
Scand J Gastroenterol; 1992 Nov; 27(11):968-72. PubMed ID: 1455196
[TBL] [Abstract][Full Text] [Related]
14. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation.
Nielsen ST; Beninati L; Buonato CB
Scand J Gastroenterol; 1988 Apr; 23(3):272-6. PubMed ID: 2898806
[TBL] [Abstract][Full Text] [Related]
15. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.
Miyachi Y; Yoshioka A; Imamura S; Niwa Y
Gut; 1987 Feb; 28(2):190-5. PubMed ID: 2881849
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Rhodes JM; Bartholomew TC; Jewell DP
Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey CJ; Lo Casto M
Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
Garg GP; Cho CH; Ogle CW
Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
[TBL] [Abstract][Full Text] [Related]
19. Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo.
Goerg KJ; Wanitschke R; Gabbert H; Breiling J; Franke M; Meyer zum Büschenfelde KH
Digestion; 1987; 37(2):79-87. PubMed ID: 2887473
[TBL] [Abstract][Full Text] [Related]
20. 5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid.
Clerici C; Gentili G; Pellicciari R; Gresele P; Mezzasoma AM; Giansanti M; Clementi M; Bartoli G; Balò S; Modesto R; Aburbeh AG; Morelli O; Morelli A
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):385-90. PubMed ID: 9789134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
